Highlights the clinical challenge of managing intracranial hemorrhage in patients on dabigatran given the lack of established reversal strategies at the time.
Answers are grounded in this paper and cite their sources.
Supports close monitoring for dabigatran-related ICH; leaves open optimal reversal protocols for prospective study.
BACKGROUND AND IMPORTANCE: Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke prevention agent in patients with atrial fibrillation. In comparison with warfarin, dabigatran showed superiority in stroke prevention, but lower rates of major hemorrhage and intracerebral hemorrhage. Although warfarin has a well-established reversal strategy, there is far less experience reversing dabigatran. CLINICAL PRESENTATION: We present our experience with 3 patients who experienced an intracranial hemorrhage either spontaneously or after low-energy cranial trauma and review the available literature describing dabigatran use in patients with traumatic brain injury. CONCLUSION: Intracranial hemorrhage in patients taking anticoagulants and/or antiplatelets can have either a benign or malignant clinical course. At this time, there is little experience with dabigatran reversal; however, several strategies for rapid reversal have been proposed. All patients with intracranial hemorrhage taking dabigatran should be admitted for close neurological monitoring and serial imaging. ABBREVIATIONS: aPTT, activated partial prothrombin time cSDH, chronic subdural hematoma CT, computerized tomography GCS, Glasgow Coma Scale GFR, glomerular filtration rate INR, international normalized ratio IPH, intraparenchymal hemorrhage tSAH, traumatic subarachnoid hemorrhage TT, thrombin time
No takes yet. Share an insight, caveat, or question.
Wassef et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: